The organization formerly known as the Pharmaceutical Fine Chemicals business of Clariant is now Archimica — a global fine chemicals business focused on commercialization solutions for the pharmaceutical industry. The new business consists of all assets and personnel that previously supported commercial activities for the manufacture of high-tech building blocks, regulatory starting materials, cGMP intermediates and APIs for the pharmaceutical industry.

Archimica will be headquartered in Frankfurt, Germany with manufacturing and technology development sites in the U.S., the UK, Germany, France and Italy.

Ralf Pfirmann, global business director of the new Archimica said, "For the past five years, our Pharmaceutical Fine Chemicals business has been working to implement a strategy to be a premiere supplier for the pharmaceutical industry. Going forward, this will not change. We will have the same excellent personnel working within the same frameworks at all of our global sites. This means that our technology development, process expertise, manufacturing excellence, and our state-of-the art regulatory compliance efforts will remain the same. Today we are not just a chemical business and we are not just a pharmaceutical manufacturing business, we have evolved our business model to create value for the pharmaceutical industry where they need it."

The development and commercialization of generic APIs will continue in the new organization. Also, each of the manufacturing and R&D sites previously serving the Pharmaceutical Fine Chemicals business will continue to do so under Archimica. These include Pharmaceutical Centers of Excellence in Springfield, MO, (in combination with a Puerto Rico facility) and Origgio/Isso, Italy that currently form the business' FDA/cGMP manufacturing capability. They also include sites in Bon Encontre/Tonneins, France that conduct the business' bulk sterile API manufacturing and Sandycroft, UK where high intensity chemistry as well as the manufacture of APIs is practiced. The Frankfurt, Germany site is the business' global Pharmaceutical Services Technology Center, focusing on expanding the use of leading chemical and biological technologies in the development of new processes.